Gynotech is a developer of SMAT solutions for uro-gynecology conditions such as vaginal prolapse and urinary incontinence.
Gynotech has developed the first smart, dynamic pessary that automatically adjust its size in response to the changing intr-abdominal pressures and thus provides a much better prevention of prolapse and urinary leakages.
Chairman & CEO (D.Sc. in biochemistry and pharmacology) - Meir served for 20 years as CEO of Israeli and Canadian hi-tech companies, including CEO of two technological incubators. Earlier, he was a senior executive at ICL (Israel Chemical Ltd.) Group.
.
Hylomorph
Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Hylomorph is a newly formed medical device company based in Switzerland with a breakthrough technology to improve the biocompatibility of medical implants. Upon implantation, devices such as cardiac implantable electronic devices or breast implants are perceived as a foreign body resulting in the formation of fibrotic (scar) tissue around the implant over time. This can lead to severe complications both for patient and surgeon during revision surgery resulting in additional costs of care.
Hylomorph has developed a novel material from biocellulose which has a unique macro and micro morphology disrupting both protein and fibroblast adhesion, blocking the process of fibrotic capsule formation. This material can be formed into a variety of shapes which can be placed around the implantable device, both acting as a physical barrier and an active anti-fibrotic membrane.
Hylomorph is applying this technology to the two largest implantable medical device markets: cardiac implantable electronic devices, and breast implants, aiming to reduce significantly the clinical and economic problems associated with fibrotic capsule formation. Clinical trials will commence in 2018 with CE mark and FDA 510k clearance planned for 2020.
ID-NEST is currently developping a new, disruptive way to rebuild vascular bifurcations. Targeted indications are Aortic Arch Aneurysms and Compressed Veins. Our technology focuses on a patented way to connect 2 self-expandable stents on site, in order to restore native vessel capacities.
Scientific Committee comprises Pr Nabil Chakfé (Strasbourg), Dr Philippe Nicolini (Lyon), Pr Gerard O'Sullivan (Galway), Pr Stephen Black (London), Pr Armando Mansilha (Porto), Dr Olivier Hartung (Marseille).
Operational Team comprises:
. C. Tézenas du Montcel, CEO, MBA, 20+ years of experience at Management level in the Vascular Devices industry,
. William Wiecek, COO, 25+ years in the Medical Devices Industry. QA/RA specialist.
Financial Summary
We're looking at a 10 millions € need, with a first slice of 2 millions € now to fund the Technological Development, followed by a 8 millions € slice to fund the clinicals
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Junction Therapeutics, a clinical stage biotech developing siRNA technology for the safe controlled modulation of blood brain barrier (BBB) permeability. This will revolutionise the treatment of neurological conditions by selectively allowing small molecules to enter the brain as treatment as well as allowing pathological molecules to be removed. The BBB expresses high levels of tight-junction proteins, claudin-5 and occludin to prevent unwanted entry of solutes. Administration of siRNA complexes targeting claudin-5 (JT-01) and occludin + claudin-5 (JT-02) selectively and reversibly loosens the tight junction barrier component, this therapy renders the BBB reversibly permeable to compounds up to 10 kD for up to 36 hours. At Junction, we have taken advantage of previous issues with siRNA technology as we need only 30% suppression and can be delivered by peripheral injection for BBB permeability. Our completed FDA-observed GLP primate studies shown Glioblastoma Multiforme as a disease model to demonstrate JT-01 as an effective BBB drug delivery platform and treatment of cerebral edema. Our JT-02 programme is shown promise halting neurological conditions and symptoms such as reducing Aβ1-40 levels and increase cognitive ability in Alzheimer’s Disease model over 12 months of treatment. Our treatments are safe and no significant toxicity has been found.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Juvabis is a recent Universität Zürich spin-off with a strong ETH-UZH IP portfolio in the field of anti-infective therapeutics. Juvabis is pre-seed stage currently operating out of UZH premises, about to enter the CTI coaching programme and bound to attract series A funding by the end of this year.
Albeit being a young startup company, our preclinical portfolio of leads has already been quite successful with the first candidate bound to enter non-clinical GLP tox in October 2017, thanks to an accelerator-type of partnership with the IMI ND4BB programme (http://nd4bb-enable.eu).
At Karmagenes, we do behavioral genetic and psychological analysis to improve people’s personal and professional life. Karmagenes SA is a Swiss-based startup and its scientific team has developed proprietary algorithms that a) provide an unbiased view of genetic potential through DNA-based personality test, b) assess current personality through KG5+ psychological tool and c) offer custom advice through in-house psychologist regarding career orientation, partnership and wellbeing.
Since more than 450mio people have a bad mental being affecting their capacity ‘’to work and to love’’, our next step is to apply our technology to a life coaching app combining psychological and genetic data analysis coupled with artificial intelligence.
At your fingertip, you will have access to our existing network of coaches and specialists who can help you improve your overall wellbeing by understanding the real you.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Retinitis Pigmentosa (RP), Leber’s Congenital Amaurosis (LCA) and Stargardt’s Disease (STGD) are rare eye diseases leading to severe vision impairment or blindness. Within the eye, they cause degeneration of the photoreceptors responsible for conversion of light into signals to be sent to the brain. The conditions are inherited and caused by ~250 different gene mutations. They affect a combined 450,000 people within the EU, Japan and the US. To date, no treatment is available for RP, LCA and STGD. Mireca wants to develop drug candidate LP–DF 003 which uses a novel approach for the treatment of the conditions. In contrast to current gene therapies, which address specific gene mutations, Mireca’s approach is significantly broader and assumed suitable to target at least one third of the various gene mutations. Based on the promising outcomes of the EU (FP7) funded DRUGSFORD project, Mireca benefits from completed pre-clinical pharmacology and initial safety testing, an existing orphan drug designation granted by the EMA, a GMP-compliant production process, 3 patent applications and exclusive licensing agreements. Beyond currently planned product developments, Mireca has access to a platform technology for the potential treatment of several neurodegenerative diseases. Mireca has been set up as a German limited liability company (“GmbH”) located in Tuebingen (~40 kilometers south of DE-Stuttgart). Mireca’s experienced international management team combines broad and deep scientific as well as business experience. Mireca wants to transition LP-DF003 into clinical studies and aims to obtain market authorizations for RP, LCA and STGD treatment products starting in the year 2024.
Musli Thyropeutics is a clinical stage pharmaceutical company addressing high-grade cancers. The company's patented fix-dose combination is based on recent scientific findings. Musli is targeting Glioblastoma Multiforme and Brain Metastases as-well-as Lung cancer and other aggressive high-grade cancers. Musli is preparing for Phase 2/3 clinical trials starting in 2018. Our innovative adjunct approach to current standard of care is expected to facilitate quick penetration to some of the largest markets in oncology, composing a multi-billion opportunity.
Our fight starts by diagnosing bacterial resistance to antibiotics in record time, using microfluidics.
Our test will help doctors determine the most appropriate antibiotic treatment for their patients and provide same-day results, which will reduce the spread of resistant bacteria and significantly lower the burden on healthcare costs.
This revolutionary scientific development is supported by a Proof of Concept from the lab of Prof. Levenberg, Dean of the Technion Biomedical Engineering Faculty.
Diane Abensur is a Franco-Israeli entrepreneur and the CEO & co-founder of Nanosynex. She established the company in 2017 after graduating from the Technion Institute of Technology International M.B.A (Haifa, Israel). She graduated from E.D.H.E.C Business School (Lille, France) and obtained her Master Degree in Business Management. In between, she worked as a junior analyst in consulting and M&A on healthcare deals in Paris and New York.
Responsive Web Design powered by 